{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:07:15Z","timestamp":1791288435120,"version":"4.3.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.diagmicrobio.2005.06.004","type":"journal-article","created":{"date-parts":[[2005,8,15]],"date-time":"2005-08-15T11:05:49Z","timestamp":1124103949000},"page":"173-179","source":"Crossref","is-referenced-by-count":80,"title":["In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)"],"prefix":"10.1016","volume":"52","author":[{"given":"Samuel K.","family":"Bouchillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Hsiung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dowzicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/13543784.12.3.379","article-title":"Novel antibacterial agents for the treatment of serious Gram-positive infections","volume":"12","author":"Abbanat","year":"2003","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib2","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1128\/AAC.46.3.892-895.2002","article-title":"In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain","volume":"46","author":"Betriu","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib3","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/jac\/dkf196","article-title":"Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia","volume":"50","author":"Betriu","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0732-8893(01)00269-3","article-title":"In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases","volume":"40","author":"Biedenbach","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/jac\/dkg289","article-title":"In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides","volume":"52","author":"Cercenado","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib6","series-title":"Performance standard for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib7","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.47.3.972-978.2003","article-title":"Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1","volume":"47","author":"Dean","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ijantimicag.2004.07.007","article-title":"Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections","volume":"24","author":"Fritsche","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0732-8893(99)00092-9","article-title":"Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates","volume":"36","author":"Gales","year":"2000","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jac\/49.3.479","article-title":"Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)","volume":"49","author":"Henwood","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0924-8579(02)00124-3","article-title":"Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US","volume":"20","author":"Karlowsky","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib13","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/AAC.46.8.2540-2545.2002","article-title":"Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States","volume":"46","author":"Karlowsky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/AAC.48.1.366-367.2004","article-title":"In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae","volume":"48","author":"Kitzis","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib15","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1592\/phco.22.17.1517.34117","article-title":"Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination","volume":"22","author":"Mercier","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/AAC.47.1.400-404.2003","article-title":"Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates","volume":"47","author":"Milatovic","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1128\/AAC.47.2.529-532.2003","article-title":"Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model","volume":"47","author":"Nannini","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib18","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"National Committee for Clinical Laboratory Standards","year":"2003"},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib19","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1128\/AAC.48.11.4479-4481.2004","article-title":"Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem","volume":"48","author":"Pachon-Ibanez","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib21","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0149-2918(04)90070-7","article-title":"Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients","volume":"26","author":"Postier","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2003.05.010","article-title":"Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres","volume":"23","author":"Rhomberg","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"Suppl. T1","key":"10.1016\/j.diagmicrobio.2005.06.004_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jac.a020891","article-title":"The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project","volume":"46","author":"Schito","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib11","series-title":"Tygacil Product Insert","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/AAC.47.2.665-669.2003","article-title":"AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis","volume":"47","author":"Visalli","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib25","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1128\/AAC.46.10.3164-3167.2002","article-title":"Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria","volume":"46","author":"Wallace","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/jac\/36.1.225","article-title":"Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycylcyclines","volume":"36","author":"Weiss","year":"1995","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.06.004_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.diagmicrobio.2004.08.007","article-title":"In vitro activities of tigecycline against clinical isolates from Shanghai, China","volume":"50","author":"Zhang","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889305001367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889305001367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T17:48:36Z","timestamp":1552758516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889305001367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0732889305001367"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2005.06.004","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}